Literature DB >> 28410291

Role of Induction Chemotherapy Prior to Chemoradiation in Head and Neck Squamous Cell Cancer-Systematic Review and Meta-analysis.

Liat Vidal1, Irit Ben Aharon, Dror Limon, Ezra Cohen, Aron Popovtzer.   

Abstract

The objective of this study was to review and assess the impact of additional induction chemotherapy to concomitant chemoradiation in head and neck squamous cell cancer. We performed a comparative systematic review and meta-analysis of clinical trials of induction chemotherapy + chemoradiation and chemoradiation alone in this setting. We identified trials randomizing 1314 patients (published 2004-2015). A non-statistically significant trend was observed in favor of induction chemotherapy + chemoradiation on overall survival (hazard ratio, 0.88; 95% confidence interval, 0.75-1.04). Disease control was superior in the induction chemotherapy + chemoradiation group (hazard ratio, 0.69; 95% confidence interval, 0.57-0.83). The rate of complete response improved with induction chemotherapy compared with concomitant chemoradiation (relative risk, 1.52; 95% confidence interval, 1.20-1.92). This study showed no benefit of induction chemotherapy + chemoradiation on overall survival. However, improved complete response rate and death certificate-only registrations may imply that selected patients may benefit from induction chemotherapy.

Entities:  

Mesh:

Year:  2017        PMID: 28410291     DOI: 10.1097/PPO.0000000000000253

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  7 in total

1.  Relationship between CD44high/CD133high/CD117high cancer stem cells phenotype and Cetuximab and Paclitaxel treatment response in head and neck cancer cell lines.

Authors:  Ana Livia Silva Galbiatti-Dias; Glaucia Maria Mendonça Fernandes; Marcia Maria Urbanin Castanhole-Nunes; Luiza Fernandes Hidalgo; Carlos Henrique Viesi Nascimento Filho; Rosa Sayoko Kawasaki-Oyama; Leticia Antunes Muniz Ferreira; Patricia Matos Biselli-Chicote; Érika Cristina Pavarino; Eny Maria Goloni-Bertollo
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

2.  Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status.

Authors:  Natalie M Lowe; Jonathan M Bernstein; Kathleen Mais; Kate Garcez; Lip W Lee; Andrew Sykes; David J Thomson; Jarrod J Homer; Catharine M West; Nicholas J Slevin
Journal:  J Cancer Res Clin Oncol       Date:  2017-12-08       Impact factor: 4.553

3.  Locally Advanced Oral Tongue Cancer: Is Organ Preservation a Safe Option in Resource-Limited High-Volume Setting?

Authors:  Muntazir Hussain; Muhammad Faisal; Muhammad Abu Bakar; Tahir Muhammad; Saman Qadeer; Sameen Mohtasham; Raza Hussain; Arif Jamshed
Journal:  Ann Maxillofac Surg       Date:  2020-06-08

4.  Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced nasopharyngeal carcinoma: A retrospective propensity score matching analysis.

Authors:  Hao-Yun Tao; Ze-Jiang Zhan; Wen-Ze Qiu; Kai Liao; Ya-Wei Yuan; Rong-Hui Zheng
Journal:  Asia Pac J Clin Oncol       Date:  2021-05-04       Impact factor: 1.926

5.  In vitro and in vivo superior radiosensitizing effect of berbamine for head and neck squamous cell carcinoma.

Authors:  Hongmei Zhu; Shu Ruan; Feng Jia; Jiusheng Chu; Yong Zhu; Yongjiu Huang; Guan Liu
Journal:  Onco Targets Ther       Date:  2018-11-14       Impact factor: 4.147

6.  Transoral Robotic Surgery for Pharyngeal and Laryngeal Cancers-A Prospective Medium-Term Study.

Authors:  Chen-Chi Wang; Wen-Jiun Lin; Yi-Chun Liu; Chien-Chih Chen; Shang-Heng Wu; Shih-An Liu; Kai-Li Liang
Journal:  J Clin Med       Date:  2021-03-02       Impact factor: 4.241

7.  Three therapeutic regimens based on induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: a single center experience.

Authors:  Lin Jiang; Liang Guo; Kejing Wang; Shengye Wang; Meiyu Fang; Jianlin Lou
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.